Targeting the complement system in geographic atrophy: mechanisms and therapeutics

Introduction Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) and a leading cause of vision loss for which there are currently two FDA-approved treatments (pegcetacoplan and avacincaptad pegol). The complement system, a major effector arm of innate and adaptive immunity, has been implicated in the pathogenesis of GA. This review aims to provide a comprehensive overview of the mechanisms underlying complement dysregulation in GA and the current therapeutic strategies to treat GA via targeting the complement system.